Follicular Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Dr. Younes on Atezolizumab, Obinutuzumab, and Bendamustine in Follicular Lymphoma - OncLive



OncLive
 
Dr. Younes on Atezolizumab, Obinutuzumab, and Bendamustine in Follicular Lymphoma 
OncLive
Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in ...

and more » 


Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants - Lymphoma News Today



Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants 
Lymphoma News Today
Biopharmaceutical company TG Therapeutics and the National Cancer Institute's SWOG have initiated a Phase 2 trial testing three Gazyva (obinutuzumab) regimens in patients with relapsed or refractory follicular lymphoma. The trial (NCT03269669) is ...

 


FDA OKs Treatment for Advanced Follicular Lymphoma - Pharmacy Times



Curetoday.com
 
FDA OKs Treatment for Advanced Follicular Lymphoma 
Pharmacy Times
Officials with the FDA have approved obinutuzumab (Gazyva, Genentech) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to the company's press release ...
FDA Approves Gazyva for Advanced Follicular Lymphoma Curetoday.com
FDA Gives Go-Ahead to Obinutuzumab for Follicular Lymphoma Treatment Rare Disease Report
FDA Approves Genentech's Gazyva for Previously Untreated Advanced Follicular Lymphoma Business Wire (press release)
Monthly Prescribing Reference  -Healio 
all 8 news articles » 


Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting - GlobeNewswire (press release)



Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting 
GlobeNewswire (press release)
These data from the company's ongoing Phase 2 clinical trial in non-Hodgkin lymphoma (NHL) highlight exploratory response biomarkers and interim correlative data which may have the potential to further refine the clinical application of tazemetostat ...

 


Multiple gene therapy trials report high remission rates for certain lymphoma patients - Xinhua



KFGO
 
Multiple gene therapy trials report high remission rates for certain lymphoma patients 
Xinhua
Among these patients, 43 percent of DLBCL patients achieved complete remission, as did 71 percent of patients with follicular lymphoma, the second most common form of the disease. All patients who were in remission at six months are still in remission ...
Global CAR T therapy trial shows high rates of durable remission for NHL EurekAlert (press release)
Primary analysis results from Novartis pivotal JULIET trial show Kymriah? (tisagenlecleucel) sustained complete ... Markets Insider

all 6 news articles » 


Benefits Maintained With Axi-Cel Long-Term for NHL - Targeted Oncology



Targeted Oncology
 
Benefits Maintained With Axi-Cel Long-Term for NHL 
Targeted Oncology
In phase II, patients were enrolled into 2 cohorts consisting of those with diffuse large B-cell lymphoma (n = 77) and those with primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL transformed from follicular ...
Phase 2 CAR-T study reports significant remission rates at 15-month follow up EurekAlert (press release)

all 4 news articles » 


Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphoma - Healio



Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphoma 
Healio
The analysis included 108 patients (median age, 58 years) ? including seven from the phase 1 trial and 101 from the phase 2 trial ? with refractory diffuse large B-cell lymphoma, transformed follicular lymphoma or primary mediastinal large B-cell ...

 


Gazyva Wins FDA OK for Untreated Advanced Follicular Lymphoma ... - Managed Care magazine



Pharmaceutical Processing
 
Gazyva Wins FDA OK for Untreated Advanced Follicular Lymphoma ... 
Managed Care magazine
Obinutuzumab (Gazyva, Genentech) has won FDA approval for the initial treatment of advanced follicular lymphoma after improving patients' survival in trials compared with rituximab-based regimens, the current standard of care. The FDA approved ...
U.S. FDA Approves Roche's Gazyva for Untreated Follicular ... Fox Business
FDA OKs Gazyva for new lymphoma indication | PharmaLive PharmaLive (press release)
FDA approves Gazyva for new indication - The Pharma Letter The Pharma Letter

all 7 news articles » 


Follicular Lymphoma Treatment Gazyva-Chemo Combo FDA ... - Lymphoma News Today



Follicular Lymphoma Treatment Gazyva-Chemo Combo FDA ... 
Lymphoma News Today
The FDA has approved Gazyva (obinutuzumab) in combination with chemotherapy as a first-line treatment for advanced follicular lymphoma.
FDA Approves Roche's Hemophilia A Biologic and Expands ... BioPharm International

all 2 news articles » 


Combination of G100 with KEYTRUDA (pembrolizumab) Triggers ... - GlobeNewswire (press release)



Combination of G100 with KEYTRUDA (pembrolizumab) Triggers ... 
GlobeNewswire (press release)
SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today presented data from the randomized Phase 2 trial of its investigational ...

and more »